Q-omics provides the consensus-scored PUS3 profile across patient tissues and cancer cell-line models. PUS3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PUS3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PUS3 RNA expression shows 18,500 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where PUS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PUS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PUS3 survival associations across molecular data types. PUS3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PUS3 RNA expression–survival associations across cancer types. High PUS3 expression shows unfavorable associations in ACC, KIRP, HNSC and SCLC, but favorable associations in LGG and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PUS3 RNA expression.
This table summarizes PUS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PUS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PUS3 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, COAD, HNSC and STAD. The KIRC box plot shows higher PUS3 RNA expression in tumor versus normal tissue (log2 FC = +0.395, t-test p < 0.001).
This table shows molecular features associated with PUS3 in patient tissues and cancer cell lines. In patient samples, PUS3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PUS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and CNS.
